{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:38:34Z","timestamp":1792852714286,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Bayer Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.kint.2024.02.024","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T22:24:26Z","timestamp":1711405466000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-425X","authenticated-orcid":false,"given":"Wolfgang C.","family":"Winkelmayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie W.A.","family":"Lensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi I.","family":"Thadhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-2014","authenticated-orcid":false,"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1kos F.","family":"Pap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstin","family":"Thelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Solms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila J.M.","family":"Ingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.02.024_bib1","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 annual data report: epidemiology of kidney disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.02.024_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2016.1.188","article-title":"Thrombosis and anticoagulation in the setting of renal or liver disease","volume":"2016","author":"Ribic","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.kint.2024.02.024_bib3","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","article-title":"Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target","volume":"100","author":"Eikelboom","year":"2021","journal-title":"Kidney int"},{"key":"10.1016\/j.kint.2024.02.024_bib4","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.02.024_bib5","first-page":"19","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2024.02.024_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.02.024_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2024.02.024_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.02.024_bib9","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.02.024_bib10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.02.024_bib11","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A\u00a0multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.02.024_bib12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.02.024_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXI(Rx) in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.02.024_bib14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/psp4.12663","article-title":"PK\/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.kint.2024.02.024_bib15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.kint.2024.02.024_bib16","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.kint.2024.02.024_bib17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.2215\/CJN.11650919","article-title":"Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation","volume":"15","author":"Mavrakanas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.02.024_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1523-1755.2003.00101.x","article-title":"Elevated risk of stroke among patients with end-stage renal disease","volume":"64","author":"Seliger","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.02.024_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1681\/ASN.2011070658","article-title":"Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients","volume":"23","author":"Yang","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.02.024_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40697-014-0021-x","article-title":"The three-year incidence of major hemorrhage among older adults initiating chronic dialysis","volume":"1","author":"Sood","year":"2014","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.kint.2024.02.024_bib21","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.113.004777","article-title":"Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis","volume":"129","author":"Shah","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.02.024_bib22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.02.024_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A\u00a0randomized controlled trial comparing apixaban to the vitamin K-antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.02.024_bib24","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1681\/ASN.2006020156","article-title":"International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality","volume":"17","author":"Yoshino","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.02.024_bib25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJMoa2304820","article-title":"Effect of hemodiafiltration or hemodialysis on mortality in kidney failure","volume":"389","author":"Blankestijn","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824001960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824001960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:58:38Z","timestamp":1732791518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824001960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0085253824001960"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.02.024","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.03.029","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}